IKBIP (IKBKB interacting protein) is a conserved protein with dual roles in cellular regulation and cancer progression. As a p53 target gene, IKBIP possesses pro-apoptotic function 1, though its expression in malignancies contradicts this intrinsic role. In glioblastoma, IKBIP functions as a driver of tumor progression by directly binding and stabilizing CDK4, preventing its ubiquitination-mediated degradation and promoting G1/S cell cycle progression 2. IKBIP is significantly upregulated across multiple cancer types and independently predicts poor prognosis in glioblastoma, papillary renal cell carcinoma, and esophageal squamous cell carcinoma 3, 4, 5. Mechanistically, IKBIP promotes tumor cell proliferation and invasion through AKT signaling pathway activation 5. Beyond cancer, IKBIP shows disease relevance in neurodegenerative conditions; elevated IKBIP expression correlates with Parkinson's disease pathology in circulating blood cells alongside neuroinflammation markers 6. Additionally, increased urinary IKBIP positively correlates with microalbumin levels and diabetic nephropathy progression 7. Clinically, IKBIP-high tumors exhibit immunosuppressive microenvironments with elevated tumor-associated macrophages, fibroblasts, and regulatory T cells, correlating with reduced chemotherapy responsiveness 8, 1. These findings establish IKBIP as a pan-cancer oncogene and promising prognostic biomarker with potential therapeutic targeting value.